In today’s briefing:
- Mirxes Pre-IPO: Early Signs of Commercialization Challenges
Mirxes Pre-IPO: Early Signs of Commercialization Challenges
- Mirxes, a Singapore-headquartered RNA technology company with a focus on cancer screening, plans to raise up to US$100m via a Hong Kong listing.
- In this insight, we examine its key product, GASTROClear’s technical and clinical data. We also look at the competitive landscape.
- We are of the view that the company’s product, despite improving the accuracy over incumbent competitors marginally, is not a killer product and will face challenges in ramping up sales.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
